| |
| |
|
| Insider
Information: |
Silverstein Jonathan |
| Relationship: |
Director, 10% Owner |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
50,683 |
|
|
Indirect Shares
|
27,740,790 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$453,042,837 |
|
|
| Total
Shares |
27,791,473 |
|
|
| Total
Value |
$453,042,837 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 17.4%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Avanir Pharmaceuticals |
AVNR |
Director |
2007-03-01 |
50,683 |
2007-03-01 |
2,335,259 |
Premium* |
|
|
Insulet Corp |
PODD |
Director |
2007-05-18 |
0 |
2007-05-18 |
1,568,841 |
Premium* |
|
|
Nxstage Medical, Inc. |
NXTM |
Director, 10% Owner |
|
0 |
2008-07-23 |
5,555,556 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director, 10% Owner |
2013-11-20 |
0 |
2013-11-20 |
9,941,551 |
Premium* |
|
|
Roka Bioscience, Inc. |
ROKA |
Director, 10% Owner |
|
0 |
2014-07-22 |
30,378 |
Premium* |
|
|
Glaukos Corp |
GKOS |
Director |
2015-06-30 |
0 |
2018-03-06 |
0 |
Premium* |
|
|
Scpharmaceuticals Inc. |
SCPH |
Director |
2017-11-21 |
0 |
2017-11-21 |
2,576,532 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director, 10% Owner |
2018-01-30 |
0 |
2018-01-30 |
4,830,387 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
Director, 10% Owner |
2020-02-03 |
0 |
2020-10-02 |
902,286 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2004-09-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,875,000 |
|
- |
|
| NXTM |
Nxstage Medical, Inc. |
Director |
– • • |
2008-07-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,555,556 |
|
- |
|
| ROKA |
Roka Bioscience, Inc. |
Director |
– • • |
2014-07-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,732 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2006-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
6,435 |
6,435 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
officerTitle |
– • – |
2007-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
44,248 |
50,683 |
0 |
- |
|
| PODD |
Insulet Corp |
Director |
– • – |
2007-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,568,841 |
1,568,841 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • • |
2013-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
7,511,930 |
7,511,930 |
0 |
- |
|
| ROKA |
Roka Bioscience, Inc. |
Director |
– • • |
2014-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,832,364 |
26,762 |
0 |
- |
|
| GKOS |
Glaukos Corp |
Director |
– • • |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
2,882,064 |
27,194 |
0 |
- |
|
| GKOS |
Glaukos Corp |
Director |
– • • |
2015-06-30 |
4 |
OE |
$0.00 |
$0 |
I/I |
27,607 |
27,455 |
0 |
- |
|
| SCPH |
Scpharmaceuticals Inc. |
Director |
– • – |
2017-11-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,576,532 |
2,576,532 |
0 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • • |
2018-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,297,054 |
4,297,054 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Director |
– • • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
4,114,962 |
606,286 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • • |
2013-11-20 |
4 |
OE |
$0.17 |
$296,601 |
I/I |
1,744,711 |
9,234,475 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2005-04-08 |
4 |
B |
$2.20 |
$1,980,000 |
I/I |
900,000 |
8,775,000 |
2.1 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2005-10-20 |
4 |
B |
$2.65 |
$1,500,001 |
I/I |
566,038 |
9,341,038 |
2.1 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2006-05-31 |
4 |
S |
$9.79 |
$6,159,095 |
I/I |
(629,121) |
1,706,137 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2006-05-31 |
4 |
A |
$9.79 |
$3,407 |
D/D |
348 |
6,783 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2006-05-31 |
4/A |
D |
$9.79 |
$6,159,095 |
I/I |
(629,121) |
1,706,137 |
|
- |
|
| RLYP |
Relypsa Inc |
Director |
– • • |
2013-11-20 |
4 |
B |
$11.00 |
$7,834,112 |
I/I |
712,192 |
9,941,551 |
2.25 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • • |
2013-11-20 |
4 |
D |
$11.00 |
$300,102 |
I/I |
(27,282) |
9,229,359 |
0 |
- |
|
| ROKA |
Roka Bioscience, Inc. |
Director |
– • • |
2014-07-22 |
4 |
B |
$12.00 |
$4,599,996 |
I/I |
383,333 |
30,378 |
2.25 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • • |
2018-01-30 |
4 |
B |
$15.00 |
$7,999,995 |
I/I |
533,333 |
4,830,387 |
2.25 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
Director |
– • • |
2020-02-03 |
4 |
B |
$17.00 |
$9,501,096 |
I/I |
558,888 |
176,500 |
2.25 |
- |
|
| GKOS |
Glaukos Corp |
Director |
– • • |
2015-06-30 |
4 |
D |
$18.00 |
$211,212 |
I/I |
(11,734) |
27,344 |
0 |
- |
|
43 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
